Skip to main content
Back to Trials
NCT07712575PHASE1RecruitingAccepts Healthy Volunteers

A Study of V132 in Healthy Older Participants (V132-001)

Merck Sharp & Dohme LLC

Start Date

8/12/2026

Completion Date

6/21/2028

Summary

The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.

Eligibility Criteria

Age Range: 50 years to 75 years

Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) within 18.0 to 35.0 kg/m\^2 (inclusive) Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination * Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study

Interventions

BIOLOGICAL

V132 Formulation 1

BIOLOGICAL

V132 Formulation 2

BIOLOGICAL

V132 Formulation 3

BIOLOGICAL

PREVNAR 20™

BIOLOGICAL

CAPVAXIVE™

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy

Locations

Anaheim Clinical Trials ( Site 0006)

Anaheim, California 92801

United States

Velocity Clinical Research, Hallandale Beach ( Site 0003)

Hallandale, Florida 33009

United States

Research Centers of America ( Hollywood ) ( Site 0009)

Hollywood, Florida 33024

United States

QPS-MRA, LLC-Early Phase ( Site 0001)

South Miami, Florida 33143

United States

Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)

Springfield, Missouri 65802

United States

Velocity Clinical Research Lincoln ( Site 0007)

Lincoln, Nebraska 68510

United States

Velocity Clinical Research, Omaha ( Site 0008)

Omaha, Nebraska 68134

United States

Remington-Davis, Inc. ( Site 0005)

Columbus, Ohio 43215

United States

Velocity Clinical Research, Providence ( Site 0010)

East Greenwich, Rhode Island 02818

United States

University of Texas Medical Branch ( Site 0004)

League City, Texas 77573

United States